Nivolumab, approved for adjuvant therapy in resected esophageal cancer, is typically administered at 240 mg every 2 weeks (Q2W) or 480 mg every 4 weeks (Q4W).
However, data on the 480 mg Q4W regimen as an initial therapy are limited.
In this study, we evaluated its safety and efficacy.
